Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

ALBO

Albireo Pharma (ALBO)

Albireo Pharma Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALBO
DataHoraFonteTítuloCódigoCompanhia
14/02/202410:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALBOAlbireo Pharma Inc
09/03/202308:14Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ALBOAlbireo Pharma Inc
03/03/202308:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202318:53Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202318:49Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202318:32Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202318:29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202313:29Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202313:24Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:ALBOAlbireo Pharma Inc
27/02/202318:06Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ALBOAlbireo Pharma Inc
14/02/202318:01Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ALBOAlbireo Pharma Inc
14/02/202310:30GlobeNewswire Inc.FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille SyndromeNASDAQ:ALBOAlbireo Pharma Inc
27/01/202319:29Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:ALBOAlbireo Pharma Inc
23/01/202310:13Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:ALBOAlbireo Pharma Inc
19/01/202318:12Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:ALBOAlbireo Pharma Inc
10/01/202308:07Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:ALBOAlbireo Pharma Inc
21/12/202218:06Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ALBOAlbireo Pharma Inc
20/12/202218:30GlobeNewswire Inc.Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ALBOAlbireo Pharma Inc
19/12/202210:30GlobeNewswire Inc.Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMANASDAQ:ALBOAlbireo Pharma Inc
08/12/202214:35TipRanksWedbush Reaffirms Their Buy Rating on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
06/12/202210:30GlobeNewswire Inc.Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of DirectorsNASDAQ:ALBOAlbireo Pharma Inc
09/11/202210:30GlobeNewswire Inc.Albireo to Participate in Jefferies London Healthcare ConferenceNASDAQ:ALBOAlbireo Pharma Inc
09/11/202208:46TipRanksWedbush Remains a Buy on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
09/11/202208:35TipRanksH.C. Wainwright Remains a Buy on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
08/11/202218:33Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALBOAlbireo Pharma Inc
08/11/202218:01GlobeNewswire Inc.Albireo Reports Q3 2022 Financial Results and Business UpdateNASDAQ:ALBOAlbireo Pharma Inc
07/11/202210:30GlobeNewswire Inc.Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC TypesNASDAQ:ALBOAlbireo Pharma Inc
03/11/202209:30GlobeNewswire Inc.Albireo Announces 2022 SPARK Grant WinnersNASDAQ:ALBOAlbireo Pharma Inc
02/11/202209:30GlobeNewswire Inc.Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary AtresiaNASDAQ:ALBOAlbireo Pharma Inc
01/11/202209:30GlobeNewswire Inc.Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022NASDAQ:ALBOAlbireo Pharma Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALBO